These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

894 related items for PubMed ID: 25323470

  • 1. Experience of pediatric osteosarcoma of the extremity at a single institution in Taiwan: prognostic factors and impact on survival.
    Hung GY, Yen HJ, Yen CC, Chen WM, Chen PC, Wu HT, Chiou HJ, Chang WH, Hsu HE.
    Ann Surg Oncol; 2015 Apr; 22(4):1080-7. PubMed ID: 25323470
    [Abstract] [Full Text] [Related]

  • 2. Developing a prognostic model for patients with localized osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate: A single-center experience of 237 patients.
    Nataraj V, Batra A, Rastogi S, Khan SA, Sharma MC, Vishnubhatla S, Bakhshi S.
    J Surg Oncol; 2015 Nov; 112(6):662-8. PubMed ID: 26381138
    [Abstract] [Full Text] [Related]

  • 3. Comparison of long-term outcome between doublet and triplet neoadjuvant chemotherapy in non-metastatic osteosarcoma of the extremity.
    Hong S, Shin SJ, Jung M, Jeong J, Lee YJ, Shin KH, Roh JK, Rha SY.
    Oncology; 2011 Nov; 80(1-2):107-17. PubMed ID: 21677455
    [Abstract] [Full Text] [Related]

  • 4. Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy.
    Tabone MD, Kalifa C, Rodary C, Raquin M, Valteau-Couanet D, Lemerle J.
    J Clin Oncol; 1994 Dec; 12(12):2614-20. PubMed ID: 7989936
    [Abstract] [Full Text] [Related]

  • 5. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.
    Ferrari S, Smeland S, Mercuri M, Bertoni F, Longhi A, Ruggieri P, Alvegard TA, Picci P, Capanna R, Bernini G, Müller C, Tienghi A, Wiebe T, Comandone A, Böhling T, Del Prever AB, Brosjö O, Bacci G, Saeter G, Italian and Scandinavian Sarcoma Groups.
    J Clin Oncol; 2005 Dec 01; 23(34):8845-52. PubMed ID: 16246977
    [Abstract] [Full Text] [Related]

  • 6. Neoadjuvant chemotherapy for osteosarcoma of the extremities with synchronous lung metastases: treatment with cisplatin, adriamycin and high dose of methotrexate and ifosfamide.
    Bacci G, Briccoli A, Ferrari S, Saeter G, Donati D, Longhi A, Manfrini M, Bertoni F, Rimondini S, Monti C, Forni C.
    Oncol Rep; 2000 Dec 01; 7(2):339-46. PubMed ID: 10671683
    [Abstract] [Full Text] [Related]

  • 7. Neoadjuvant and adjuvant chemotherapy with high-dose ifosfamide, doxorubicin, cisplatin and high-dose methotrexate in non-metastatic osteosarcoma of the extremities: a phase II trial in Japan.
    Kudawara I, Aoki Y, Ueda T, Araki N, Naka N, Nakanishi H, Matsumine A, Ieguchi M, Mori S, Myoui A, Kuratsu S, Hashimoto N, Yoshikawa H.
    J Chemother; 2013 Feb 01; 25(1):41-8. PubMed ID: 23433444
    [Abstract] [Full Text] [Related]

  • 8. Comparative outcome of Thai pediatric osteosarcoma treated with two protocols: the role of high-dose methotrexate (HDMTX) in a single institute experience.
    Choeyprasert W, Pakakasama S, Sirachainan N, Songdej D, Chuansumrit A, Anurathapan U, Hongeng S, Nartthanarung A.
    Asian Pac J Cancer Prev; 2014 Feb 01; 15(22):9823-9. PubMed ID: 25520112
    [Abstract] [Full Text] [Related]

  • 9. Marginal resection for osteosarcoma with effective neoadjuvant chemotherapy: long-term outcomes.
    Xu M, Xu S, Yu X.
    World J Surg Oncol; 2014 Nov 11; 12():341. PubMed ID: 25391880
    [Abstract] [Full Text] [Related]

  • 10. Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1.
    Ferrari S, Ruggieri P, Cefalo G, Tamburini A, Capanna R, Fagioli F, Comandone A, Bertulli R, Bisogno G, Palmerini E, Alberghini M, Parafioriti A, Linari A, Picci P, Bacci G.
    J Clin Oncol; 2012 Jun 10; 30(17):2112-8. PubMed ID: 22564997
    [Abstract] [Full Text] [Related]

  • 11. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.
    Meyers PA, Schwartz CL, Krailo MD, Healey JH, Bernstein ML, Betcher D, Ferguson WS, Gebhardt MC, Goorin AM, Harris M, Kleinerman E, Link MP, Nadel H, Nieder M, Siegal GP, Weiner MA, Wells RJ, Womer RB, Grier HE, Children's Oncology Group.
    J Clin Oncol; 2008 Feb 01; 26(4):633-8. PubMed ID: 18235123
    [Abstract] [Full Text] [Related]

  • 12. Metastatic osteosarcoma.
    Daw NC, Billups CA, Rodriguez-Galindo C, McCarville MB, Rao BN, Cain AM, Jenkins JJ, Neel MD, Meyer WH.
    Cancer; 2006 Jan 15; 106(2):403-12. PubMed ID: 16353204
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Outcomes in non-metastatic treatment naive extremity osteosarcoma patients treated with a novel non-high dosemethotrexate-based, dose-dense combination chemotherapy regimen 'OGS-12'.
    Bajpai J, Chandrasekharan A, Talreja V, Simha V, Chandrakanth MV, Rekhi B, Khurana S, Khan A, Vora T, Ghosh J, Banavali SD, Gupta S.
    Eur J Cancer; 2017 Nov 15; 85():49-58. PubMed ID: 28888849
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities.
    Serra M, Scotlandi K, Reverter-Branchat G, Ferrari S, Manara MC, Benini S, Incaprera M, Bertoni F, Mercuri M, Briccoli A, Bacci G, Picci P.
    J Clin Oncol; 2003 Feb 01; 21(3):536-42. PubMed ID: 12560446
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.